

## AUDITED FINANCIAL RESULTS FOR THE YEAR

Sr. No.	Particulars		
		Quarter ended on 31/03/2008	Quarter ended on 31/03/2007
1	Net Sales / Income from Operations	3,003.05	1,054.39
2	Other Income	44.19	53.47
3	<b>Total Income (1+ 2)</b>	3,047.24	1,107.86
4	Expenditure		
	a) (Increase)/Decrease in Stock in Trade	260.83	(972.96)
	b) Consumption of Raw Materials	2,120.10	1,656.76
	c) Purchase of Traded goods		
	d) Employee Cost	106.98	74.55
	e) Depreciation	40.95	38.72
	f) Other Expenditure	259.82	545.32
	g) Total	2,788.68	1,342.39
5	Interest	180.53	94.59
6	Exceptional items	-	-
7	<b>Profit from Ordinary Activities before tax</b>	78.03	(329.11)
8	Tax expenses	(2.25)	9.34
9	<b>Profit from Ordinary Activities after tax</b>	80.27	(319.78)
10	Extraordinary Items	-	-
11	<b>Net Profit for the period (9-10)</b>	80.27	(319.78)
12	Paid-up equity share capital (Face value Rs. 10/-)	1,050.06	1,050.06
13	Reserves excluding revaluation reserves (As per Balance Sheet of previous accounting year)		
14	Earning per Equity Shares (EPS)		
	Basic	0.76	(3.05)
	Diluted	0.76	(4.10)
15	Public shareholding		
	- Number of Shares	5744000	5844300
	- Percentage of Shareholding	54.70	55.66

### SEGMENTWISE REVENUE, RESULTS AND CAPITAL EMPLOYED

Particulars		
	Quarter ended on 31/03/2008	Quarter ended on 31/03/2007
<b>Segment Revenue (Net)</b>		
Pharmaceuticals	3,003.05	1,054.39
Construction	-	-
Gross Revenues	3,003.05	1,054.39
<b>Segment Results</b>		

<b>Profit before tax and Interest</b>		
Pharmaceuticals	209.27	(240.22)
Construction	-	(1.48)
Total Segment Results	209.27	(241.70)
Less : Interest	180.52	94.59
Add : Net unallocable Income	49.29	7.18
Total Profit before Tax	78.04	(329.11)
<b>Segment Capital Employed</b>		
<b>(Segment Assets Less Segment Liabilities)</b>		
Pharmaceuticals	563.87	(2,227.68)
Construction	(275.00)	4,124.03
Total Capital Employed	288.87	2,247.67

**Notes:-**

- 1 The above results as reviewed by the Audit Committee were taken on record by the Board of Directors at it's mee
- 2 The Statutory Auditors of the Company have conducted a Limited Review of the above results.
- 3 The details of number of investors complaints for the quarter ended 31st March, 2008:  
Beginning - 0, Received - 18 , Disposed Off - 18 and Pending - 0.
- 4 Corresponding figures of the previous year/ quarter have been regrouped / restated wherever necessary.
- 5 The Board of Directors have recommended a dividend of 5% aggregating to Rs. 52.50 lacs. Together with the cc the total payout works to 61.42 lacs.

For and on behalf of the B  
**HIRAN ORGOCHEM LIM**

**Sd/-**

Place : Mumbai  
Date : 28th June, 2008

**Kantilal M. Hiran**  
**Chairman & Managing D**

**ENDED 31ST MARCH, 2008**

(Rs. In Lacs)

<b>REVIEWED</b>	<b>AUDITED</b>	
<b>Nine months ended on 31/12/2007</b>	<b>Accounting Year ended on 31/03/2008</b>	<b>Accounting Year ended on 31/03/2007</b>
8,902.02	11,905.07	10,788.22
223.81	268.00	175.20
9,125.83	12,173.07	10,963.42
(34.33)	226.50	(1,868.03)
7,067.61	6,118.30	6,390.73
-	3,069.42	3,900.60
277.51	384.49	345.48
142.32	183.27	162.34
753.44	1,013.26	1,301.06
8,206.55	10,995.23	10,232.18
499.58	680.11	463.52
-	-	-
419.70	497.73	267.72
111.72	109.47	160.07
307.98	388.26	107.65
-	-	-
307.98	388.26	107.65
1,050.06	1,050.06	1,050.06
	7,695.52	7,368.69
2.93	3.70	1.03
2.93	4.96	1.36
5,844,000.00	5744000	5844300
55.65	54.70	55.66

(Rs. In Lacs)

<b>UNAUDITED</b>	<b>AUDITED</b>	
<b>Nine months ended on 31/12/2007</b>	<b>Accounting Year ended on 31/03/2008</b>	<b>Accounting Year ended on 31/03/2007</b>
8,902.02	11,905.07	11,801.44
-	-	-
8,902.02	11,905.07	11,801.44

834.48	1,043.75	616.60
-	-	(1.48)
834.48	1,043.75	615.12
499.58	680.11	463.52
84.80	134.09	116.12
419.70	497.74	267.72
4,602.62	5,166.49	4,543.17
4,124.03	3,849.03	4,124.03
8,726.65	9,015.52	8,667.20

Meeting held on 28th June, 2008

Corporate Dividend Tax of Rs. 8.92 lacs

Board of Directors of  
**UNITED**

Director